{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"198","upperLimit":"279","value":"272"},{"groupId":"OG001","lowerLimit":"268","upperLimit":"268","value":"268"},{"groupId":"OG002","lowerLimit":"257","upperLimit":"349","value":"303"},{"groupId":"OG003","lowerLimit":"193","upperLimit":"237","value":"215"},{"groupId":"OG004","lowerLimit":"297","upperLimit":"297","value":"297"},{"groupId":"OG005","lowerLimit":"130","upperLimit":"634","value":"227"},{"groupId":"OG006","lowerLimit":"121","upperLimit":"391","value":"236"},{"groupId":"OG007","lowerLimit":"248","upperLimit":"439","value":"324"},{"groupId":"OG008","lowerLimit":"169","upperLimit":"445","value":"254"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"13"}],"units":"Participants"}],"title":"Cycle 1-End of infusion"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"308","upperLimit":"308","value":"308"},{"groupId":"OG002","lowerLimit":"338","upperLimit":"338","value":"338"},{"groupId":"OG003","lowerLimit":"404","upperLimit":"404","value":"404"},{"groupId":"OG005","lowerLimit":"205","upperLimit":"364","value":"262"},{"groupId":"OG006","lowerLimit":"249","upperLimit":"249","value":"249"},{"groupId":"OG007","lowerLimit":"300","upperLimit":"381","value":"323"},{"groupId":"OG008","lowerLimit":"244","upperLimit":"420","value":"365"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"4"}],"units":"Participants"}],"title":"Cycle 3-End of Infusion"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"13"}],"units":"Participants"}],"description":"Median, minimum, and maximum concentration of AMG 479 at specified time points.","dispersionType":"Full Range","groups":[{"description":"AMG 479 18 mg/kg IV plus AMG 655 1 mg/kg IV (day 1 of each Q3W cycle)\n\nAMG 479: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.\n\nAMG 655: AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.","id":"OG000","title":"Part 1 Cohort 1"},{"description":"AMG 479 18 mg/kg IV plus AMG 655 3 mg/kg IV (day 1 of each Q3W cycle)\n\nAMG 479: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.\n\nAMG 655: AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.","id":"OG001","title":"Part 1 Cohort 2"},{"description":"AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg IV (day 1 of each Q3W cycle)\n\nAMG 479: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.\n\nAMG 655: AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.","id":"OG002","title":"Part 1 Cohort 3"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Non-squamous NSCLC","id":"OG003","title":"Part 2 Cohort 1"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Squamous Non -Small Cell Lung Cancer (NSCLC)","id":"OG004","title":"Part 2 Cohort 2"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Colorectal Cancer (CRC)","id":"OG005","title":"Part 2 Cohort 3"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Pancreatic Cancer","id":"OG006","title":"Part 2 Cohort 4"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Ovarian Cancer","id":"OG007","title":"Part 2 Cohort 5"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Sarcoma","id":"OG008","title":"Part 2 Cohort 6"}],"paramType":"MEDIAN","populationDescription":"PK population = All subjects in the full analysis set who underwent blood sampling for PK evaluation during the study.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 end of infusion; Cycle 3 Day 1 end of infusion (each cycle is 28 days, each infusion is up to 1 hour)","title":"To Evaluate the Concentration Level of AMG 479","type":"SECONDARY","unitOfMeasure":"μg/mL"}